The Software Apocalypse Hit Veeva Systems — Here's Why We're Still Interested

The Software Apocalypse Hit Veeva Systems — Here's Why We're Still Interested

Veeva Systems has been hammered by the AI-driven software selloff — but when you look past the stock chart, the fundamentals tell a completely different story. Zero debt, over $6 billion in cash, $1.4 billion in free cash flow, and a reverse DCF suggesting the market is pricing in only 5% growth. That seems like a very easy hurdle for Veeva to clear.

In this episode, Kasey breaks down why Veeva is far more than a boring CRM company. Built specifically for the biopharma and life sciences industry,

Veeva has embedded itself into every stage of the drug development process — from R&D and clinical trials through manufacturing compliance and global regulatory filings.


We cover:

- What Veeva actually does — the four-segment cloud stack explained

- FY2026 results: $3.2B revenue, 16% year-over-year growth

- The balance sheet: $6B+ cash, zero debt

- Free cash flow growing at a 16% CAGR on a per-share basis

- Is AI a genuine threat to Veeva — or a tailwind?

- CEO Peter Gassner's case for AI as symbiotic, not disruptive

- The real bottleneck in getting drugs to patients — and where Veeva fits

- A reverse DCF valuation walkthrough: what growth rate is actually priced in?

We lay out the full case and leave the conclusion where it belongs — with you.

Want deeper research and live discussion? Join our Semi Insider community at chipstockinvestor.com. New members can access the Discord server until April 15th.

Disclaimer: Content is for general information and educational purposes only and does not constitute specific investment advice. All investing involves risk. Nick and Kasey hold a position in Veeva Systems.

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(459)

IBM NanoStack CFET: Turning Patents Into Chip Royalties

IBM NanoStack CFET: Turning Patents Into Chip Royalties

IBM just unveiled NanoStack, its take on the CFET transistor architecture that succeeds gate-all-around as the next step in chip scaling — and it could turn IBM's patent portfolio into a real semicond...

10 Heinä 15min

Jensen Called Marvell a $1T Stock — We're Not Buying It

Jensen Called Marvell a $1T Stock — We're Not Buying It

Marvell (NASDAQ: MRVL) stock has surged since Jensen Huang called it the next trillion-dollar company — we ran a reverse DCF on the Q1 FY2027 earnings to see if the rally is justified.Marvell just pos...

7 Heinä 11min

Memory & Optical Stocks Up 100%+ in 2026: Why We're Not Selling (Micron, SK Hynix, SanDisk, Lumentum)

Memory & Optical Stocks Up 100%+ in 2026: Why We're Not Selling (Micron, SK Hynix, SanDisk, Lumentum)

Memory and optical semiconductor stocks have been the standout trade of 2026, with holdings like Micron, SK Hynix, and SanDisk up well over 100% year-to-date on tight supply and rising pricing. In thi...

4 Heinä 11min

Cybersecurity & Capital Allocation: Is Rubrik (RBRK) a Buy?

Cybersecurity & Capital Allocation: Is Rubrik (RBRK) a Buy?

Rubrik (RBRK) stock is down near $70 after peaking above $89 — but its subscription ARR is still growing over 30%. Here's the reverse DCF and margin math behind why the recovery has stalled.Rubrik (NY...

2 Heinä 10min

Micron's $100 Billion Backlog: Are Take-or-Pay Agreements Changing the Memory Cycle?

Micron's $100 Billion Backlog: Are Take-or-Pay Agreements Changing the Memory Cycle?

The memory chip industry has historically been plagued by vicious boom-and-bust cycles, but Micron is taking aggressive steps to rewrite the rules. In this episode of Chip Stock Investor, we discuss S...

30 Kesä 17min

AppLovin Stock: Is It Time to Buy the Dip?

AppLovin Stock: Is It Time to Buy the Dip?

AppLovin stock posted 59% revenue growth and a 70% free cash flow margin in Q1 2026—numbers that look more like cheat codes than a real business. We break down what makes the Axon 2.0 machine learning...

27 Kesä 12min

AI Data Center Supply Chains & Indium Phosphide: A Look at Oxford Instruments

AI Data Center Supply Chains & Indium Phosphide: A Look at Oxford Instruments

In this episode, CSI is cutting through the social media noise to bring you a vintage Chip Stock Investor breakdown of the semiconductor supply chain. Today, we are putting the spotlight on Oxford Ins...

25 Kesä 14min

SpaceX IPO, Orbital Data Centers & Investing in Quantum Computing | CSI with Simon Erickson of 7investing

SpaceX IPO, Orbital Data Centers & Investing in Quantum Computing | CSI with Simon Erickson of 7investing

In this episode of CSI Live, Nick sits down with Simon Erickson from 7investing to unpack the latest breakthroughs in high-tech infrastructure. The conversation kicks off with a look at the massive Sp...

24 Kesä 31min

Suosittua kategoriassa Liike-elämä ja talous

sijotuskasti
psykopodiaa-podcast
mimmit-sijoittaa
ostan-asuntoja-podcast
rss-rahapodi
rss-oivalluksia-rahasta-elamasta
rahapuhetta
rss-inderes
asuntoasiaa-paivakirjat
rss-markkinointitrippi
rss-sami-miettinen-neuvottelija
rss-kahavia-ja-markkinointia-podcast
inderespodi
hyva-paha-johtaminen
vapauta-supervoimasi-podcast
rss-kaikki-koroista
rss-ammattipodcast
rss-stressivapaa-johtaja-nakokulmia-henkilokohtaiseen-kasvuun
rss-perho-rajoilla
kultaiset-hoitajat